NewAmsterdam Pharma Warrant
NAMSW
11 hedge funds and large institutions have $18.8M invested in NewAmsterdam Pharma Warrant in 2024 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 2 closing their positions.
101% more capital invested
Capital invested by funds: $9.32M → $18.8M (+$9.44M)
0% more funds holding
Funds holding: 11 → 11 (0)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
0.05% less ownership
Funds ownership: 1.48% → 1.43% (-0.05%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AAA
Affinity Asset Advisors
New York
|
+$270K |
| 2 |
WAM
Wolverine Asset Management
Chicago,
Illinois
|
+$137K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$26.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
-$218K |
| 2 |
HF
HRT Financial
New York
|
-$146K |
| 3 |
TFM
TFC Financial Management
Boston,
Massachusetts
|
-$43.3K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
FLSM
1
Frazier Life Sciences Management
Palo Alto,
California
| $7.13M | – | – | – |
|
|
RCM
2
RA Capital Management
Boston,
Massachusetts
| $4.75M | – | – | – |
|
|
AAA
3
Affinity Asset Advisors
New York
| $3.33M | +$270K | +24,961 | +12% |
|
|
BCLSI
4
Bain Capital Life Sciences Investors
Boston,
Massachusetts
| $1.43M | – | – | – |
|
|
DM
5
Deerfield Management
New York
| $1.32M | – | – | – |
|
|
LCM
6
Laurion Capital Management
New York
| $237K | – | – | – |
|
|
HF
7
HRT Financial
New York
| $191K | -$146K | -13,465 | -50% |
|
|
WAM
8
Wolverine Asset Management
Chicago,
Illinois
| $181K | +$137K | +12,693 | New |
|
|
VI
9
Vestcor Inc
Fredericton,
New Brunswick, Canada
| $137K | – | – | – |
|
|
10
UBS Group
Zurich,
Switzerland
| $35.4K | +$26.8K | +2,481 | New |
|
11
CIBC Private Wealth Group
Atlanta,
Georgia
| $14.3K | – | – | – |
|
|
MIM
12
Monashee Investment Management
Boston,
Massachusetts
| – | -$218K | -31,189 | Closed |
|
|
TFM
13
TFC Financial Management
Boston,
Massachusetts
| – | -$43.3K | -6,181 | Closed |
|
NAMSW Hedge Fund Activity: Q4 2024 in Review
11 of the 7,594 institutional investors tracked by Wall St. Rank reported a position in NewAmsterdam Pharma Warrant (NAMSW) for Q4 2024, worth a combined $18.8M — up 101% from $9.32M a quarter earlier.
Fund positioning in NAMSW was balanced in Q4 2024: 2 funds opened new positions, 2 closed out, 1 added to existing stakes and 1 trimmed.
The largest buyer was Affinity Asset Advisors, adding an estimated $270K. The largest seller was Monashee Investment Management, exiting entirely with an estimated $218K sold.
- 11 institutional investors held NewAmsterdam Pharma Warrant (NAMSW) as of Q4 2024, unchanged from Q3 2024.
- Funds reported $18.8M of NewAmsterdam Pharma Warrant stock for Q4 2024, up 101% quarter-over-quarter.
- 2 funds opened new NewAmsterdam Pharma Warrant positions in Q4 2024 and 2 closed out, a net change of 0 holders.
- The largest NewAmsterdam Pharma Warrant buyer in Q4 2024 was Affinity Asset Advisors, an estimated $270K added.
- The largest NewAmsterdam Pharma Warrant seller in Q4 2024 was Monashee Investment Management, an estimated $218K sold.
Based on aggregated 13F filings for Q4 2024.